Amylyx's Relyvrio pulls in $71M in revenue
Amylyx’s ALS drug Relyvrio brought in $71.4 million in revenue in the first quarter of the year, far surpassing expectations for a CNS therapy approved less than a year ago.
Relyvrio is Amylyx’s only approved product. It’s available in the US and Canada, where it goes by the name Albrioza, and the company said it expects a decision in Europe this summer. It had $21.9 million in sales in the final three months of last year, the first full quarter it was on the market in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.